Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

UNCOVERED: Merck - Caught on Camera

This Merck (MRK) Stock Bullish Diagonal Trade Targets a Price of $130 by June 18

A bullish diagonal spread is an advanced option trade and generally not suitable for beginners, but it can have its place within an option portfolio.

Barchart

Merck Just Made a Big Bet on a New Cancer Growth Engine

Merck's $6.7 billion Terns acquisition bolsters its oncology pipeline while reinforcing its strong margins, steadily growing dividend, and long-term growth.

MarketBeat

3 Undervalued Names Too Cheap to Ignore

Three prominent names across the biopharma and consumer staples spaces offer the potential for value plays with room for fundamental growth as well.

MarketBeat

From analysis to the latest developments in health,
read the most diverse news in one place.

Experimental pill may offer new cholesterol-lowering option for millions

There are other pills that patients can add to their statin

The Independent UK

Promising vaccine for aggressive melanoma could unlock the body’s potential to fight cancer

A personalised mRNA vaccine developed by Moderna and Merck shows lasting benefits for patients with high-risk skin cancer.

Euronews

New personalized skin cancer treatment shows success in preventing return of high-risk melanoma

Patients with severe melanoma who received the treatment were 49% less likely to die or have their cancer return, pharmaceutical companies Moderna and Merck announced in five-year findings.

The Independent UK

3 “Forever Stocks” to Hold When the Market Won’t Sit Still

Chevron, Colgate-Palmolive, and Merck highlight how dividends, durable businesses, and long-term growth drivers can support a buy-and-hold investment strategy

MarketBeat

Read news from The Economist, FT, and more,
with one subscription

Today in ‘great’ America: Donald Trump decides to prove he can’t negotiate to save his life

What an awful deal.

We Got This Covered

Life-saving therapies are being delayed as research funding dries up

Letter: Dr Carol S Leonard writes that mRNA vaccines are a way forward for those with melanoma, but hopes are dashed by financial cuts

The Guardian - UK

More drug companies sign on to Trump’s health exchange that promises to lower prescription prices

Administration officials say the ‘Trump Rx’ website should be up and running next month

The Independent UK

Boss of drugs giant GSK declares US best place to invest

Dame Emma Walmsley said the US was still leading the way for new drugs and vaccines.

Evening Standard

What will be the cost of Keir Starmer’s new medicines deal with Donald Trump? British lives

More than £3bn that could have been used for UK patients will go to big pharma for its branded products, says Guardian columnist Aditya Chakrabortty

The Guardian - UK

Dividend Stocks for 2026: Where to Invest as the Market Cools

These three dividend heavyweights offer attractive yields and upside potential heading into what could be an uncertain 2026.

MarketBeat

FDA opens safety review of injectable RSV drugs approved for babies and toddlers

Federal health officials are reviewing the safety of two injectable drugs used to protect babies and toddlers from the RSV virus

The Independent UK

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

These 2 High-Yield Dividend Stocks Are Some of the Safest Buys Right Now

Merck and Duke Energy stand out as rare “safe yield” plays, pairing 3%+ dividends with solid earnings growth, reasonable payout ratios, and durable demand drivers in healthcare and regulated utilities.

Barchart

2 Dividend Stocks to Buy Now for Big Payout Growth Ahead

Merck and Qualcomm combine strong cash flow with steady dividend growth, signaling potential for meaningful payout increases ahead.

Barchart

The Dow Jones Looks Ready for Death, But These 3 Blue-Chip Stocks Have More Life (and Gains) Ahead

These three stocks have healthy charts in an index that’s looking sick.

MarketBeat

Healthcare Rotation Underway: 3 Stocks Leading the Charge

Are healthcare stocks finally back in fashion? After years of underperformance, a healthcare rotation is underway, led by these three innovative drug makers.

Get all your
news in one place.

100's of premium titles.
One news app.

MarketBeat

Merck Writes a $9.2 Billion Check for a Flu Drug That Could Change Everything

Merck's multi-billion-dollar acquisition of Cidara Therapeutics is a strategic move to secure a new era of growth with a high-potential antiviral asset.

Benzinga

Merck Makes Big Bet On Flu Protection With Cidara Buyout

Merck Co. Inc. (NYSE:MRK) on Friday agreed to acquire Cidara Therapeutics, Inc. (NASDAQ:CDTX) for $221.50 per share in cash, for a total transaction value of approximately $9.2 billion.

The Guardian - UK

‘Patients will suffer’: tales from the frontline of the UK pharma crisis

The pricing standoff between government and industry has stalled research and put thousands of jobs at risk

Benzinga

Merck's New Cancer Therapy Combo Shows Significant Edge Over Rivals In Renal Cancer

On Tuesday, Merck Co. Inc. (NYSE:MRK) and Eisai shared topline data from the Phase 3 LITESPARK-011 trial of the dual oral regimen of Welireg (belzutifan) plus Lenvima (lenvatinib).

Benzinga

Invo Fertility Stock Is Plunging After White House Announcement

INVO Fertility Inc (NASDAQ:IVF) shares are trading lower on Thursday as investors book profits following White House announcements aimed at making fertility treatments more affordable and accessible.

Benzinga

Merck's Keytruda Plus Chemo Regimen Shows Overall Survival Benefit In Recurrent Ovarian Cancer Patients

Merck Co. Inc. (NYSE:MRK) announced data from the Phase 3 KEYNOTE-B96 trial (ENGOT-ov65) of Keytruda (pembrolizumab) in combination with chemotherapy (paclitaxel) with or without Roche Holdings AG’s (OTC:RHHBY) Avastin (bevacizumab).

Benzinga

Merck's New HIV Treatment Works As Well As Top Drug In Late Trials

The relentless pursuit of innovative treatments in the pharmaceutical industry continues to reshape the landscape of chronic disease management. Merck Co. Inc. (NYSE:MRK) on Wednesday announced additional data from two Phase 3 studies of a two-drug regimen of doravirine/islatravir (DOR/ISL) in adults with virologically suppressed HIV-1 infection.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.